Methamphetamine- and Trauma-Induced Brain Injuries: Comparative Cellular and Molecular Neurobiological Substrates

Biological Psychiatry

Volumn 66, Issue 2, 2009, Pages 118-127

  Gold, Mark S ^a,b,c   Kobeissy, Firas H ^a,b   Wang, Kevin K W ^a,e   Merlo, Lisa J ^b   Bruijnzeel, Adriaan W ^b   Krasnova, Irina N ^d   Cadet, Jean Lud ^d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e BANYAN BIOMARKERS INC   (United States)

Author keywords

II spectrin; brain injury; calpain; caspase; methamphetamine; neuroproteomics; neurotoxicity; proteolysis; psychoproteomics

Indexed keywords

CALPAIN; CALPASTATIN; CASPASE; CASPASE INHIBITOR; FODRIN; METHAMPHETAMINE; TAU PROTEIN;

ACUTE DRUG ADMINISTRATION; APOPTOSIS; BRAIN CELL; BRAIN FUNCTION; BRAIN REGION; CELL ACTIVATION; CELL DEATH; DEGRADATION; DRUG ABUSE; DRUG DEPENDENCE; HUMAN; LIFESPAN; MENTAL DISEASE; METHAMPHETAMINE ADDICTION; NERVE CELL LESION; NEUROBIOLOGY; NEUROLOGICAL COMPLICATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEOMICS; REVIEW; STRUCTURE ANALYSIS; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; CELL DEATH; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; METHAMPHETAMINE; NEURONS; PROTEOMICS; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 67549106801     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2009.02.021     Document Type: Review

References (103)

1. Wise R.A. Drug-activation of brain reward pathways. Drug Alcohol Depend 51 (1998) 13-22
2. Koob G.F. A role for brain stress systems in addiction. Neuron 59 (2008) 11-34
3. Cadet J.L., Krasnova I.N., Jayanthi S., and Lyles J. Neurotoxicity of substituted amphetamines: Molecular and cellular mechanisms. Neurotoxicity Res 11 (2007) 183-202
4. Moppett I.K. Traumatic brain injury: Assessment, resuscitation and early management. Br J Anaesth 99 (2007) 18-31
5. Traumatic Brain Injury: Hope Through Research. http://www.ninds.nih.gov/disorders/tbi/detail_tbi.htm Accessed July 25, 2008
6. Hoffmann B., Duwecke C., and von Wild K.R. Neurological and social long-term outcome after early rehabilitation following traumatic brain injury. 5-year report on 240 TBI patients. Acta Neurochir Suppl 79 (2002) 33-35
7. Mateer C.A., and Sira C.S. Cognitive and emotional consequences of TBI: Intervention strategies for vocational rehabilitation. Neurol Rehab 21 (2006) 315-326
8. Himanen L., Portin R., Isoniemi H., Helenius H., Kurki T., and Tenovuo O. Cognitive functions in relation to MRI findings 30 years after traumatic brain injury. Brain Inj 19 (2005) 93-100
9. Sherer M., Stouter J., Hart T., Nakase-Richardson R., Olivier J., Manning E., et al. Computed tomography findings and early cognitive outcome after traumatic brain injury. Brain Inj 20 (2006) 997-1005
10. Salmond C.H., and Sahakian B.J. Cognitive outcome in traumatic brain injury survivors. Curr Opin Crit Care 11 (2005) 111-116
11. Tenovuo O. Pharmacological enhancement of cognitive and behavioral deficits after traumatic brain injury. Curr Opin Neurol 19 (2006) 528-533
12. Finnie J.W., and Blumbergs P.C. Traumatic brain injury. Vet Pathol 39 (2002) 679-689
13. Reilly P.L. Brain injury: The pathophysiology of the first hours. "Talk and Die revisited". J Clin Neurosci 8 (2001) 398-403
14. Wennersten A., Holmin S., and Mathiesen T. Characterization of Bax and Bcl-2 in apoptosis after experimental traumatic brain injury in the rat. Acta Neuropathol 105 (2003) 281-288
15. Hall E.D., Sullivan P.G., Gibson T.R., Pavel K.M., Thompson B.M., and Scheff S.W. Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: More than a focal brain injury. J Neurotrauma 22 (2005) 252-265
16. McIntosh T.K., Juhler M., and Wieloch T. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998. J Neurotrauma 15 (1998) 731-769
17. Sullivan P.G., Rabchevsky A.G., Waldmeier P.C., and Springer J.E. Mitochondrial permeability transition in CNS trauma: Cause or effect of neuronal cell death?. J Neurosci Res 79 (2005) 231-239
18. Rego A.C., Monteiro N.M., Silva A.P., Gil J., Malva J.O., and Oliveira C.R. Mitochondrial apoptotic cell death and moderate superoxide generation upon selective activation of non-desensitizing AMPA receptors in hippocampal cultures. J Neurochem 86 (2003) 792-804
19. Czogalla A., and Sikorski A.F. Spectrin and calpain: A "target" and a "sniper" in the pathology of neuronal cells. Cell Mol Life Sci 62 (2005) 1913-1924
20. Golstein P., and Kroemer G. Cell death by necrosis: Towards a molecular definition. Trends Biochem Sci 32 (2007) 37-43
21. Hutchison J.S., Derrane R.E., Johnston D.L., Gendron N., Barnes D., Fliss H., et al. Neuronal apoptosis inhibitory protein expression after traumatic brain injury in the mouse. J Neurotrauma 18 (2001) 1333-1347
22. Stridh H., Kimland M., Jones D.P., Orrenius S., and Hampton M.B. Cytochrome c release and caspase activation in hydrogen peroxide- and tributyltin-induced apoptosis. FEBS Lett 429 (1998) 351-355
23. Hirsch T., Susin S.A., Marzo I., Marchetti P., Zamzami N., and Kroemer G. Mitochondrial permeability transition in apoptosis and necrosis. Cell Biol Toxicol 14 (1998) 141-145
24. Yuan J., Lipinski M., and Degterev A. Diversity in the mechanisms of neuronal cell death. Neuron 40 (2003) 401-413
25. Fulda S., and Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006) 4798-4811
26. Wallach D., Boldin M., Varfolomeev E., Beyaert R., Vandenabeele P., and Fiers W. Cell death induction by receptors of the TNF family: Towards a molecular understanding. FEBS Lett 410 (1997) 96-106
27. Wallach D. Apoptosis. Placing death under control. Nature 388 (1997) 125-126
28. Huang Y., and Wang K.K. The calpain family and human disease. Trends Mol Med 7 (2001) 355-362
29. McGinnis K.M., Gnegy M.E., Park Y.H., Mukerjee N., and Wang K.K. Procaspase-3 and poly(ADP)ribose polymerase (PARP) are calpain substrates. Biochem Biophys Res Commun 263 (1999) 94-99
30. Saatman K.E., Murai H., Bartus R.T., Smith D.H., Hayward N.J., Perri B.R., et al. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci U S A 93 (1996) 3428-3433
31. Zhang Z., Ottens A.K., Shankar S., Kobeissy F., Tei F., Hayes R.L., et al. Calpain-mediated collapsing response mediator protein-2 proteolysis following acute traumatic or neurotoxic injury. J Neurotrauma 24 (2007) 460-472
32. Kobeissy F.H., Ottens A.K., Zhang Z., Liu M.C., Denslow N.D., Dave J.R., et al. Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol Cell Proteomics 5 (2006) 1887-1898
33. Wang K.K., Nath R., Raser K.J., and Hajimohammadreza I. Maitotoxin induces calpain activation in SH-SY5Y neuroblastoma cells and cerebrocortical cultures. Arch Biochem Biophys 331 (1996) 208-214
34. Pike B.R., Zhao X., Newcomb J.K., Posmantur R.M., Wang K.K., and Hayes R.L. Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. Neuroreport 9 (1998) 2437-2442
35. Farkas O., Polgar B., Szekeres-Bartho J., Doczi T., Povlishock J.T., and Buki A. Spectrin breakdown products in the cerebrospinal fluid in severe head injury-preliminary observations. Acta Neurochir (Wien) 147 (2005) 855-861
36. Pike B.R., Flint J., Dutta S., Johnson E., Wang K.K., and Hayes R.L. Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem 78 (2001) 1297-1306
37. Liu H.M., and Sturner W.Q. Extravasation of plasma proteins in brain trauma. Forensic Sci Int 38 (1988) 285-295
38. Pineda J.A., Wang K.K., and Hayes R.L. Biomarkers of proteolytic damage following traumatic brain injury. Brain Pathol 14 (2004) 202-209
39. Squier M.K., Miller A.C., Malkinson A.M., and Cohen J.J. Calpain activation in apoptosis. J Cell Physiol 159 (1994) 229-237
40. Wang K.K., Ottens A., Haskins W., Liu M.C., Kobeissy F., Denslow N., et al. Proteomics studies of traumatic brain injury. Int Rev Neurobiol 61 (2004) 215-240
41. Bernath E., Kupina N., Liu M.C., Hayes R.L., Meegan C., and Wang K.K. Elevation of cytoskeletal protein breakdown in aged Wistar rat brain. Neurobiol Aging 27 (2006) 624-632
42. Wang K.K., Posmantur R., Nath R., McGinnis K., Whitton M., Talanian R.V., et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem 273 (1998) 22490-22497
43. Pike B.R., Zhao X., Newcomb J.K., Wang K.K., Posmantur R.M., and Hayes R.L. Temporal relationships between de novo protein synthesis, calpain and caspase 3-like protease activation, and DNA fragmentation during apoptosis in septo-hippocampal cultures. J Neurosci Res 52 (1998) 505-520
44. Pineda J.A., Lewis S.B., Valadka A.B., Papa L., Hannay H.J., Heaton S.C., et al. Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma 24 (2007) 354-366
45. Siman R., McIntosh T.K., Soltesz K.M., Chen Z., Neumar R.W., and Roberts V.L. Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis 16 (2004) 311-320
46. Kobeissy F.H., Warren M.W., Ottens A.K., Sadasivan S., Zhang Z., Gold M.S., et al. Psychoproteomic analysis of rat cortex following acute methamphetamine exposure. J Proteome Res 7 (2008) 1971-1983
47. Liu M.C., Akle V., Zheng W., Dave J.R., Tortella F.C., Hayes R.L., et al. Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biol Chem Series J 394 (2006) 715-725
48. Opii W.O., Nukala V.N., Sultana R., Pandya J.D., Day K.M., Merchant M.L., et al. Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury. J Neurotrauma 24 (2007) 772-789
49. Homer B.D., Solomon T.M., Moeller R.W., Mascia A., DeRaleau L., and Halkitis P.N. Methamphetamine abuse and impairment of social functioning: A review of the underlying neurophysiological causes and behavioral implications. Psychol Bull 134 (2008) 301-310
50. Albertson T.E., Derlet R.W., and Van Hoozen B.E. Methamphetamine and the expanding complications of amphetamines. West J Med 170 (1999) 214-219
51. Scott J.C., Woods S.P., Matt G.E., Meyer R.A., Heaton R.K., Atkinson J.H., et al. Neurocognitive effects of methamphetamine: A critical review and metal-analysis. Neuropsychol Rev 17 (2007) 275-297
52. Darke S., Kaye S., McKetin R., and Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27 (2008) 253-262
53. Gonzalez R., Rippeth J.D., Carey C.L., Heaton R.K., Moore D.J., Schweinsburg B.C., et al. Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend 76 (2004) 181-190
54. Bechara A. Decision making, impulse control and loss of willpower to resist drugs: A neurocognitive perspective. Nat Neurosci 8 (2005) 1458-1463
55. Mandyam C.D., Wee S., Eisch A.J., Richardson H.N., and Koob G.F. Methamphetamine self-administration and voluntary exercise have opposing effects on medial prefrontal cortex gliogenesis. J Neurol Sci 27 (2007) 11442-11450
56. Schoenbaum G., Saddoris M.P., Ramus S.J., Shaham Y., and Setlow B. Cocaine-experienced rats exhibit learning deficits in a task sensitive to orbitofrontal cortex lesions. Eur J Neurosci 19 (2004) 1997-2002
57. Schoenbaum G., Setlow B., Nugent S.L., Saddoris M.P., and Gallagher M. Lesions of orbitofrontal cortex and basolateral amygdala complex disrupt acquisition of odor-guided discriminations and reversals. Learning and Memory 10 (2003) 129-140
58. Schoenbaum G., and Shaham Y. The role of orbitofrontal cortex in drug addiction: A review of preclinical studies. Biol Psychiatry 63 (2008) 256-262
59. Caracuel A., Verdejo-Garcia A., Vilar-Lopez R., Perez-Garcia M., Salinas I., Cuberos G., et al. Frontal behavioral and emotional symptoms in Spanish individuals with acquired brain injury and substance use disorders. Arch Clin Neuropsychol 23 (2008) 447-454
60. Lange R.T., Iverson G.L., and Franzen M.D. Comparability of neuropsychological test profiles in patients with chronic substance abuse and mild traumatic brain injury. Clin Neuropsychol 22 (2008) 209-227
61. Regard M., Knoch D., Gutling E., and Landis T. Brain damage and addictive behavior: A neuropsychological and electroencephalogram investigation with pathologic gamblers. Cogn Behav Neurol 16 (2003) 47-53
62. Chang L., Alicata D., Ernst T., and Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Add Abingdon Engl 102 suppl 1 (2007) 16-32
63. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158 (2001) 377-382
64. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Nakamura K., Futatsubashi M., et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 63 (2006) 90-100
65. Ballmaier M., Sowell E.R., Thompson P.M., Kumar A., Narr K.L., Lavretsky H., et al. Mapping brain size and cortical gray matter changes in elderly depression. Biol Psychiatry 55 (2004) 382-389
66. Ernst T., Chang L., Leonido-Yee M., and Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 54 (2000) 1344-1349
67. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurol Sci 28 (2008) 5756-5761
68. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2 (1996) 699-703
69. Choi H.J., Yoo T.M., Chung S.Y., Yang J.S., Kim J.I., Ha E.S., et al. Methamphetamine-induced apoptosis in a CNS-derived catecholaminergic cell line. Mol Cells 13 (2002) 221-227
70. Davidson C., Gow A.J., Lee T.H., and Ellinwood E.H. Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res 36 (2001) 1-22
71. Bowyer J.F., and Ali S. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 60 (2006) 521-532
72. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., and Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235 (1982) 93-103
73. Axt K.J., and Molliver M.E. Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse 9 (1991) 302-313
74. Cadet J.L., and Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 32 (1998) 117-131
75. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., and Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurol Sci 19 (1999) 2424-2431
76. Deng X., Cai N.S., McCoy M.T., Chen W., Trush M.A., and Cadet J.L. Methamphetamine induces apoptosis in an immortalized rat striatal cell line by activating the mitochondrial cell death pathway. Neuropharmacology 42 (2002) 837-845
77. Albers D.S., and Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275 (1995) 1104-1114
78. Di Monte D.A., Royland J.E., Jakowec M.W., and Langston J.W. Role of nitric oxide in methamphetamine neurotoxicity: Protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase. J Neurochem 67 (1996) 2443-2450
79. Jayanthi S., Deng X., Noailles P.A., Ladenheim B., and Cadet J.L. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J 18 (2004) 238-251
80. Schmued L.C., and Bowyer J.F. Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res 759 (1997) 135-140
81. Eisch A.J., and Marshall J.F. Methamphetamine neurotoxicity: Dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse 30 (1998) 433-445
82. Ellison G., and Switzer III R.C. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 5 (1993) 17-20
83. Jayanthi S., Deng X., Bordelon M., McCoy M.T., and Cadet J.L. Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex. FASEB J 15 (2001) 1745-1752
84. Deng X., Ladenheim B., Jayanthi S., and Cadet J.L. Methamphetamine administration causes death of dopaminergic neurons in the mouse olfactory bulb. Biol Psychiatry 61 (2007) 1235-1243
85. Staszewski R.D., and Yamamoto B.K. Methamphetamine-induced spectrin proteolysis in the rat striatum. J Neurochem 96 (2006) 1267-1276
86. Quinton M.S., and Yamamoto B.K. Neurotoxic effects of chronic restraint stress in the striatum of methamphetamine-exposed rats. Psychopharmacology 193 (2007) 341-350
87. Straiko M.M., Coolen L.M., Zemlan F.P., and Gudelsky G.A. The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain. Neuroscience 144 (2007) 223-231
88. Kosik K.S., and Finch E.A. map2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites: An immunocytochemical study of cultured rat cerebrum. J Neurol Sci 7 (1987) 3142-3153
89. Warren M.W., Larner S.F., Kobeissy F.H., Brezing C.A., Jeung J.A., Hayes R.L., et al. Calpain and caspase proteolytic markers colocalize with rat cortical neurons after exposure to methamphetamine and MDMA. Acta Neuropathol 114 (2007) 277-286
90. Warren M.W., Kobeissy F.H., Liu M.C., Hayes R.L., Gold M.S., and Wang K.K. Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: A similar profile to traumatic brain injury. Life Sci 78 (2005) 301-309
91. Nath R., Raser K.J., Stafford D., Hajimohammadreza I., Posner A., Allen H., et al. Non-Erythroid alpha-spectrin breakdown by calpain and interleukin 1 beta-converting-enzyme-like protease(s) in apoptotic cells: Contributory roles of both protease families in neuronal apoptosis. Biol Chem. Series J 319 (1996) 683-690
92. Wallace T.L., Vorhees C.V., Zemlan F.P., and Gudelsky G.A. Methamphetamine enhances the cleavage of the cytoskeletal protein tau in the rat brain. Neuroscience 116 (2003) 1063-1068
93. Marcus K., Schmidt O., Schaefer H., Hamacher M., van Hall A., and Meyer H.E. Proteomics-application to the brain. Int Rev Neurobiol 61 (2004) 285-311
94. Sokolov B.P., and Cadet J.L. Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness. Neuropsychopharmacology 31 (2006) 956-966
95. Iwazaki T., McGregor I.S., and Matsumoto I. Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Res 1097 (2006) 19-25
96. Iwazaki T., McGregor I.S., and Matsumoto I. Protein expression profile in the striatum of rats with methamphetamine-induced behavioral sensitization. Proteomics 7 (2007) 1131-1139
97. Yu C.G., and Geddes J.W. Sustained calpain inhibition improves locomotor function and tissue sparing following contusive spinal cord injury. Neurochem Res 32 (2007) 2046-2053
98. Ai J., Liu E., Wang J., Chen Y., Yu J., and Baker A.J. Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. J Neurotrauma 24 (2007) 960-978
99. Nimmrich V., Szabo R., Nyakas C., Granic I., Reymann K.G., Schroder U.H., et al. Inhibition of calpain prevents N-methyl-D-aspartate-induced degeneration of the nucleus basalis and associated behavioral dysfunction. J Pharmacol Exp Ther 327 (2008) 343-352
100. Warren M.W., Zheng W., Kobeissy F.H., Cheng Liu M., Hayes R.L., Gold M.S., et al. Calpain- and caspase-mediated alphaII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure. Int J Neuropsychopharmacol 10 (2007) 479-489
101. Sadasivan S., Waghray A., Larner S.F., Dunn Jr. W.A., Hayes R.L., and Wang K.K. Amino acid starvation induced autophagic cell death in PC-12 cells: evidence for activation of caspase-3 but not calpain-1. Apoptosis 11 (2006) 1573-1582
102. Jenkins L.W., Peters G.W., Dixon C.E., Zhang X., Clark R.S., Skinner J.C., et al. Conventional and functional proteomics using large format two-dimensional gel electrophoresis 24 hours after controlled cortical impact in postnatal day 17 rats. J Neurotrauma 19 (2002) 715-740
103. Freeman W.M., Brebner K., Amara S.G., Reed M.S., Pohl J., and Phillips A.G. Distinct proteomic profiles of amphetamine self-administration transitional states. Pharmacogenomics J 5 (2005) 203-214